Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
2dpVAXKwrFEpM9AY
